(Q73194063)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10566564%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Metformin as secondary therapy in a defined population with type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10566564%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

0 references

Brown JB

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10566564%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Pedula KL

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10566564%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 October 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10566564%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

published in

Clinical Therapeutics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10566564%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10566564%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10566564%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

1678-1687

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10566564%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

An overview of metformin in the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

1 reference

7 January 2021

Biguanide-associated lactic acidosis. Case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

Diabetes mellitus and cigarette smoking. Findings from the 1989 National Health Interview Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

Oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

What is the benefit of increasing the sulfonylurea dose?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

Relation of glycemic control to diabetic microvascular complications in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

The National Diabetes Education Program: changing the way diabetes is treated

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980047-2

7 January 2021

10.1016/S0149-2918(99)80047-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10566564%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference